Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 16, 2023; 11(23): 5447-5454
Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5447
Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis
Ding-Ran Wang
Ding-Ran Wang, Department of Obstetrics and Gynaecology, Peking University Third Hospital, Beijing 100191, China
Author contributions: Wang DR designed the research study, performed the research, analyzed the data, wrote the manuscript, and read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Peking University Third Hospital Department of Obstetrics and Gynaecology.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no interest relationship.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ding-Ran Wang, PhD, Attending Doctor, Department of Obstetrics and Gynaecology, Peking University Third Hospital, No. 49 Huayuan North Road, Haidian District, Beijing 100191, China. ydausidb@163.com
Received: May 24, 2023
Peer-review started: May 24, 2023
First decision: June 12, 2023
Revised: June 15, 2023
Accepted: July 18, 2023
Article in press: July 18, 2023
Published online: August 16, 2023
ARTICLE HIGHLIGHTS
Research background

Patients with endometrial cancer have an early onset of clinical symptoms, and although the prognosis for patients with early adjuvant postoperative treatment is generally good, patients who do not receive timely treatment may develop postoperative recurrence or metastasis, which has been associated with a poor prognosis and a high mortality rate, therefore requiring adjuvant postoperative treatment depending on the patient's pathology.

Research motivation

To determine the efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate and medroxyprogesterone acetate and to evaluate their safety.

Research objectives

To provide a reference for the prognosis and anesthesia of clinical operations.

Research methods

Kaplan-Meier curve analysis and log-rank test were performed to determine the potential influencing factors on the 5-year cumulative survival rate of the study patients, while Cox regression analysis was performed to identify the factors influencing the survival prognosis of endometrial cancer.

Research results

The Cox regression analysis revealed that age [hazard ratio (HR) = 4.636, 95% confidence interval (95%CI): 1.411-15.237)], pathological type (HR = 6.943, 95%CI: 2.299-20.977), molecular typing (HR = 5.789, 95%CI: 3.305-10.141), myometrial infiltration (HR = 5.768, 95%CI: 1.898-17.520) were influential factors in the prognosis of patients with early-stage high-risk endometrial cancer.

Research conclusions

The possibility of the long-term prognostic benefit of adjuvant postoperative radiotherapy in patients with early-stage high-risk endometrium is worthy of clinical consideration.

Research perspectives

Future research may investigate optimal medroxyprogesterone acetate dosage and duration for early endometrial cancer. Can explore combining medroxyprogesterone acetate with other therapies. Also, include patient-reported outcomes to understand treatment impact.